Neuro-Ophthalmology News

High alcohol use was associated with more severe neurodegeneration and smoking was linked with greater probability of MS diagnosis, according to a U.K. study published in JAMA Network Open.

In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its B-cell-depleting agent Uplizna reduced the severity of attacks in people with neuromyelitis optica spectrum disorder.

Uplizna appeared to benefit patients with neuromyelitis optica spectrum disorder who were previously treated with rituximab, according to study results published in Multiple Sclerosis and Related Disorders.

Chugai Pharmaceutical Co. released data showing Enspryng had a favorable benefit-risk profile and effectively reduced relapses over 4 years of treatment among people with a form of neuromyelitis optica spectrum disorder.

Horizon Therapeutics plc announced results of a retrospective analysis that showed Uplizna appeared to offer durable efficacy and a favorable safety profile for African American patients with neuromyelitis optica spectrum disorder.

A survey of community neurologists demonstrated four primary themes associated with the impact of the COVID-19 pandemic in this group, specifically highlighting “the unusual environment” in which these providers practice.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended Enspryng to be approved to treat neuromyelitis optica spectrum disorder in people aged 12 years and older, according to a Roche press release.

Rituximab modulated retinal atrophy in relapsing-remitting MS, with attenuating effects that may be more significant after 12 months of treatment, according to results of an observational study published in Neurology.

Black patients with MS or neuromyelitis optica spectrum disorder experienced faster repopulation of B cells 6 to 12 months after rituximab or ocrelizumab infusion compared with white patients, according to preliminary results.

Decreased ganglion cell-inner plexiform layer thickness at baseline as assessed by optical coherence tomography correlated with a four-fold greater risk for long-term disability worsening in MS, according to findings published in Neurology.